# A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer

> **NCT02748213** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 225 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Xeloda
- **DRUG:** Taxotere
- **DRUG:** Herceptin

## Key facts

- **NCT ID:** NCT02748213
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2006-03
- **Final completion:** 2008-01
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2016-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02748213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02748213, "A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02748213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*